Position in EXEL
as of Mar 31, 2026
· filed May 1, 2026
Position Value
$200,853
-$71,243 QoQ
Shares Held
4,683
-24.6% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Wealthspire Advisors, LLC holds $11,039,371 across 15 Biotechnology names. EXEL ranks #7 (1.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
8,706 | $6,726,603 | |
| 2 | GALT |
Galectin Therapeutics Inc
|
721,788 | $2,013,788 | |
| 3 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
34,359 | $850,728 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
895 | $399,653 | |
| 5 | MREO |
Mereo BioPharma Group plc
|
796,036 | $262,691 | |
| 6 | RNXT |
RenovoRx, Inc.
|
252,525 | $255,050 | |
| 7 | EXEL |
Exelixis, Inc.
This page
|
4,683 | $200,853 | |
| 8 | OLMA |
Olema Pharmaceuticals, Inc.
|
10,172 | $151,664 |
All Filings in EXEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $200,853 | 4,683 | Shares | Sole | 2026-05-01 | |
| 2025-12-31 | $272,096 | 6,208 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $196,175 | 4,750 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $220,840 | 5,010 | Shares | Sole | 2025-08-11 | |
| No filing history on record for this holder in this stock. | ||||||